In the practice of medicine, one generally prefers time tested proven path while treating and trying to prevent diseases. An innovation is usually expected to pass the test of time. The three approved COVID-19 vakcinos, two mRNA vaccines and one genetically engineered adenovirus vector DNA vaccine, are based on concepts and technologies that have never been used on human beings in the past (though few are approved for use in veterinary medicine). Inactivated vaccines stood the test of time for more than half a century and played key role in control and eradication of many infectious diseases. Were the disadvantages of good-old time-tested method of active immunity development through inactivated vaccines comprising of killed or attenuated germs heavy enough to discard altogether to opt for technologies that were never used on humans before? Apparently, the extraordinary situation presented by the pandemic seems to have superfast-tracked testing and use of the emergent, high potential vaccine and therapeutics development technologies which otherwise would have taken several years to see the light of the day.
Trys patvirtinti COVID-19 vakcinos Šiuo metu JK žmonėms skiriama didžiulė imunizacijos programa, skirta kovai su pandemija pagal valdžios nustatytų prioritetų.
- BNT162b2 (gaminta Pfizer/BioNTech): a mRNR vakcina, neša žinią apie viruso baltymo antigeno ekspresiją žmogaus ląstelėse
- iRNR-1273 (manufactured by Moderna): a mRNA Vakcinos act in the same way as above
- ChAdOx1 nCoV-2019 (pagal Oksfordas / „AstraZeneca“): iš esmės, a DNR vakcina, naudoja genetiškai modifikuotą adenovirusą kaip vektorių, pernešantį naujo koronaviruso smailės baltymo geną, ekspresuojamą žmogaus ląstelėse, kuris veikia kaip antigenas aktyviam imuniteto vystymuisi.
Visi aukščiau išvardinti trys Covid-19 vakcinos are expected to induce active immunity against novel coronavirus. The process of immunity development (both humoral and cellular) begins following exposure to antigens. In the case of mRNA vakcinos, this happens after viral spike proteins are expressed in the human cells following injection of the vaccine containing viral messenger RNA. In the case of other, immunity development happens after expression of coronavirus DNA incorporated in the adenovirus. One may argue that these vakcinos nėra tikros vakcinos griežtąja prasme, nes jos pačios nėra antigenai ir negali sukelti imuninio atsako per se, kol žmogaus ląstelėse nepavirsta į virusinius baltymus. Vakcina pagal apibrėžimą skatina aktyvaus imuniteto susidarymo procesą, tačiau šių trijų vakcinų atveju ji turi palaukti, kol viruso genai bus paversti baltymais, kurie savo ruožtu galėtų veikti kaip antigenai. Šios trys patvirtintos vakcinos yra pagrįstos technologijomis, kurios anksčiau niekada nebuvo naudojamos žmonėms.
In the last five decades or so, vakcinos have played key role in dealing with prevention of several infectious diseases (except malaria). The time-tested gold standard was to use killed inactivated germs or germ parts as vaccine. It almost always worked. This is how several infectious diseases were controlled and some eradicated too in the past.
If the current pandemic had struck humanity say a decade ago, we would still have used the good old time-tested vakcinos made using killed germs but science has progressed much in the recent past. Advances in molecular biology of genes and its potential applications in therapeutics and vaccine development coupled with encouraging results on animal models meant saying goodbye to the existing method of inducing active immunity by exposing to weakened antigens. The idea of tricking human body to produce the viral proteins in the cells that could act as antigens for initiation of antibody formation against the self-manufactured viral proteins is sleek and smart and may be the beacon of future days to come. Just that neither mRNA nor genetically modified adenovirus has ever been used on human beings to trick the body to induce active immunity. Of course, there is first time for everything new. Yes, may be in the peacetime after studying impact for little longer period including on vulnerable population.
True, these new techniques are answers to some of safety issues like reversion risks, unintentional spread or production errors etc associated with the olden types of vakcinos. Plus, new methods are better targeted – specific antibody against specific viral antigen. But someone missed to take note of something that everyone knew that this pandemic is due to coronavirus, a virus that has a recent history of several epidemics in the past two decades, and a virus known to be notorious for rapid mutation because of lack of proofreading nuclease activity, thereby implying viral antigens are not going to remain static structurally for a long period of time. Apparently, this is what the situation looks like now.
Yes indeed, clinical trials were successfully done for viral gene-based vakcinos which proved safety and efficacy well within the permissible range. The same applies to the traditional whole virion inactivated COVID-19 vaccine as well whose initial efficacy of about 70% in trial in Brazil was brought down to 50.7% after some volunteers developed mild symptoms. But then whole virion inactivated vaccines are known to elicit mild reactions due to its very nature, possibly a trade-off for active immunity against wider range of antigens.
The performance data of the three approved vakcinos in the UK, especially pertaining to level of protection provided to the vulnerable people would tell the deeper story in future. For now, if the choice of a vaccine comprising of a wide range of antigens derived from killed inactivated virus may have been better for effectiveness over a longer period of time is in oblivion. May be, for vulnerable people viz. for those at higher risk due to advanced age or comorbidities, quick induction of passive immunity through neutralizuojantys antikūnai galėjo būti geresnis pasirinkimas ir aktyvus imuniteto būdas šiaip sveikiems žmonėms.
Atrodo, kad dėl pandemijos sukeltos nepaprastos padėties buvo itin sparčiai tiriamos ir naudojamos naujos, didelio potencialo vakcinų ir terapinių priemonių kūrimo technologijos, kurioms kitu atveju būtų prireikę kelerių metų, kol jie dienos šviesą išvystų.
***
DOI: https://doi.org/10.29198/scieu/210101
***
